Archives
|
Entry
|
Blogger
|
Date
|
Location
|
|
Dendreon Recruits Aces to Board, Amgen Seeks to Raise Hit Rate, Lee Hood Startup Gets $30M, & More Seattle-Area Life Sciences News
|
Luke Timmerman |
10/15/09 |
Seattle
|
|
ZymoGenetics Plays Hardball, Targeted Genetics’ Legacy, Omeros Preps for Fall IPO, & More Seattle-Area Life Sciences News
|
Luke Timmerman |
08/27/09 |
Seattle
|
|
Seattle Genetics Trial Fills Up
|
Luke Timmerman |
08/24/09 |
Seattle
|
|
Seattle Genetics Gets $136M Total
|
Luke Timmerman |
08/13/09 |
Seattle
|
|
Seattle Genetics, Bucking the Trend, Recruits Hodgkin’s Patients at Warp Speed
|
Luke Timmerman |
08/12/09 |
Seattle
|
|
Seattle Genetics Starts New Trial
|
Luke Timmerman |
06/18/09 |
Seattle
|
|
Cell Therapeutics Shares Boom, Vulcan’s Breast Cancer Bombshell, Microsoft Buys Rosetta Assets, & More Seattle-Area Life Sciences News
|
Luke Timmerman |
06/04/09 |
Seattle
|
|
ASCO Weekend Recap: OncoGenex, Seattle Genetics, Vulcan-Backed BiPar Show Off Cancer Drug Results
|
Luke Timmerman |
06/01/09 |
Seattle
|
|
Seattle Genetics “Empowered Antibody” Wipes Out Hodgkin’s Tumors in Early Study
|
Luke Timmerman |
06/01/09 |
Seattle
|
|
Why Should the Public Care About Biotech? Why is the Answer Always Jobs?
|
Luke Timmerman |
04/24/09 |
Seattle
|
|
Genzyme Enters Seattle Hub, Oncothyreon Bets on Cancer Drugs, Pathway Nabs $40M, & More Seattle-Area Life Sciences News
|
Luke Timmerman |
04/02/09 |
Seattle
|
|
Seattle Genetics Gets Fast Track
|
Luke Timmerman |
03/30/09 |
Seattle
|
|
Souped-Up Herceptin Aims to Validate ImmunoGen’s Long-Sought Dream Cancer Drug
|
Luke Timmerman |
03/06/09 |
Boston
|
|
UW’s Gardasil Windfall, Cell Therapeutics Unloads Zevalin, Trubion Cuts Jobs, & More Seattle-Area Life Sciences News
|
Luke Timmerman |
02/26/09 |
Seattle
|
|
Seattle Genetics Starts Pivotal Trial
|
Luke Timmerman |
02/19/09 |
Seattle
|
|
Seattle Genetics Defies Gravity With Biotech’s First Underwritten Stock Sale in Six Months
|
Luke Timmerman |
02/05/09 |
Seattle
|
|
Seattle Genetics Raises $55M
|
Luke Timmerman |
01/28/09 |
Seattle
|
|
Seattle Genetics Gets Orphan Drug Status
|
Luke Timmerman |
01/26/09 |
Seattle
|
|
Dendreon Expects Results in April, Seattle Genetics Plans Hodgkin’s Trial, ImaRx Moves to Town & More Seattle-Area Life Sciences News
|
Luke Timmerman |
01/22/09 |
Seattle
|
|
Seattle Genetics Unveils Pivotal Trial Plan for “Empowered Antibody”
|
Luke Timmerman |
01/21/09 |
Seattle
|
|
Seattle Genetics Drug Fights Hodgkin’s, Frazier Sounds Off on Biotech Ventures, SBRI Pushes Malaria Vaccine, & More Seattle-Area Life Sciences News
|
Luke Timmerman |
12/11/08 |
Seattle
|
|
Seattle Genetics “Empowered Antibody” Shines at Blood Disease Meeting
|
Luke Timmerman |
12/06/08 |
Seattle
|
|
Seattle Genetics Hires Waller To Lead Regulatory Affairs, as SGN-35 Heads to Pivotal Trial
|
Luke Timmerman |
09/30/08 |
Seattle
|
|
Seattle Genetics’ Medical Point Man, Tom Reynolds, Aims to Capitalize on Hodgkin’s Drug
|
Luke Timmerman |
09/08/08 |
Seattle
|
|
Page 1 of
1 |
|
Business, life sciences, and technology news — covering Boston, Seattle, San Diego, and beyond.
© 2007-2009, Xconomy, Inc.
XCONOMY is a registered service mark of Xconomy, Inc.
All rights reserved.
Site designed by
Matthew Bouchard, produced by
Andrew Koyfman,
and powered by WordPress.
